4.7 Article

Pan-coronavirus fusion inhibitors possess potent inhibitory activity against HIV-1, HIV-2, and simian immunodeficiency virus

Journal

EMERGING MICROBES & INFECTIONS
Volume 10, Issue 1, Pages 810-821

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1080/22221751.2021.1917309

Keywords

Coronavirus; SARS-CoV-2; HIV-1; fusion inhibitor; lipopeptide

Funding

  1. National Natural Science Foundation of China [81630061]
  2. CAMS Innovation Fund for Medical Sciences [2017-I2M-1-014]

Ask authors/readers for more resources

Research on the mechanism of action of lipopeptide inhibitors such as EK1V1 and IPB02 against HIV-1 and other viruses revealed that their target is the HR1 region of HIV-1 gp41, showing different activities against HIV-1 resistant mutants. This serendipitous discovery provides critical information for the development of broad-spectrum antivirals.
EK1 peptide is a membrane fusion inhibitor with broad-spectrum activity against human coronaviruses (CoVs). In the outbreak of COVID-19, we generated a lipopeptide EK1V1 by modifying EK1 with cholesterol, which exhibited significantly improved antiviral activity. In this study, we surprisingly found that EK1V1 also displayed potent cross-inhibitory activities against divergent HIV-1, HIV-2, and simian immunodeficiency virus (SIV) isolates. Consistently, the recently reported EK1 derivative EK1C4 and SARS-CoV-2 derived fusion inhibitor lipopeptides (IPB02 similar to IPB09) also inhibited HIV-1 Env-mediated cell-cell fusion and infection efficiently. In the inhibition of a panel of HIV-1 mutants resistant to HIV-1 fusion inhibitors, EK1V1 and IPB02-based inhibitors exhibited significantly decreased or increased activities, suggesting the heptad repeat-1 region (HR1) of HIV-1 gp41 being their target. Furthermore, the sequence alignment and molecular docking analyses verified the target site and revealed the mechanism underlying the resistance. Combined, we conclude that this serendipitous discovery provides a proof-of-concept for a common mechanism of viral fusion and critical information for the development of broad-spectrum antivirals.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available